AU2002337047B2 - Novel dihydropteridinones, method for producing the same and the use thereof as medicaments - Google Patents

Novel dihydropteridinones, method for producing the same and the use thereof as medicaments Download PDF

Info

Publication number
AU2002337047B2
AU2002337047B2 AU2002337047A AU2002337047A AU2002337047B2 AU 2002337047 B2 AU2002337047 B2 AU 2002337047B2 AU 2002337047 A AU2002337047 A AU 2002337047A AU 2002337047 A AU2002337047 A AU 2002337047A AU 2002337047 B2 AU2002337047 B2 AU 2002337047B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
rac
denotes
continued
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002337047A
Other languages
English (en)
Other versions
AU2002337047A1 (en
AU2002337047B8 (en
Inventor
Eckhart Bauer
Steffen Breitfelder
Christian Eickmeier
Matthias Grauert
Matthias Hoffmann
Thorsten Lehmann-Lintz
Gerald Pohl
Jens Jurgen Quant
Norbert Redemann
Gisela Schnapp
Martin Steegmaier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AU2002337047B8 publication Critical patent/AU2002337047B8/en
Publication of AU2002337047A1 publication Critical patent/AU2002337047A1/en
Application granted granted Critical
Publication of AU2002337047B2 publication Critical patent/AU2002337047B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002337047A 2001-09-04 2002-08-30 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments Ceased AU2002337047B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10143272.0 2001-09-04
DE10143272 2001-09-04
PCT/EP2002/009728 WO2003020722A1 (de) 2001-09-04 2002-08-30 Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
AU2002337047B8 AU2002337047B8 (en) 2003-03-18
AU2002337047A1 AU2002337047A1 (en) 2003-06-05
AU2002337047B2 true AU2002337047B2 (en) 2008-01-10

Family

ID=7697637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002337047A Ceased AU2002337047B2 (en) 2001-09-04 2002-08-30 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments

Country Status (30)

Country Link
EP (1) EP1427730B1 (enrdf_load_stackoverflow)
JP (1) JP3876254B2 (enrdf_load_stackoverflow)
KR (1) KR100955589B1 (enrdf_load_stackoverflow)
CN (1) CN1551881A (enrdf_load_stackoverflow)
AR (1) AR036586A1 (enrdf_load_stackoverflow)
AT (1) ATE332898T1 (enrdf_load_stackoverflow)
AU (1) AU2002337047B2 (enrdf_load_stackoverflow)
BR (1) BRPI0212137A2 (enrdf_load_stackoverflow)
CA (1) CA2458699C (enrdf_load_stackoverflow)
CO (1) CO5560575A2 (enrdf_load_stackoverflow)
CY (1) CY1105337T1 (enrdf_load_stackoverflow)
DE (1) DE50207522D1 (enrdf_load_stackoverflow)
DK (1) DK1427730T3 (enrdf_load_stackoverflow)
EA (1) EA007062B1 (enrdf_load_stackoverflow)
EC (1) ECSP045003A (enrdf_load_stackoverflow)
ES (1) ES2268093T3 (enrdf_load_stackoverflow)
HR (1) HRP20040213A2 (enrdf_load_stackoverflow)
HU (1) HUP0401293A3 (enrdf_load_stackoverflow)
IL (2) IL160440A0 (enrdf_load_stackoverflow)
MX (1) MXPA04002067A (enrdf_load_stackoverflow)
MY (1) MY129751A (enrdf_load_stackoverflow)
NO (1) NO328804B1 (enrdf_load_stackoverflow)
NZ (1) NZ531928A (enrdf_load_stackoverflow)
PL (1) PL369740A1 (enrdf_load_stackoverflow)
PT (1) PT1427730E (enrdf_load_stackoverflow)
RS (1) RS51012B (enrdf_load_stackoverflow)
UA (1) UA76512C2 (enrdf_load_stackoverflow)
UY (1) UY27427A1 (enrdf_load_stackoverflow)
WO (1) WO2003020722A1 (enrdf_load_stackoverflow)
ZA (1) ZA200401365B (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274340B2 (en) * 2004-08-14 2012-04-05 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl) benzamide, methods for the production thereof, and use thereof as medicaments

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
DE60037321T4 (de) 1999-08-04 2010-01-07 Icagen, Inc. Benzanilide als öffner des kaliumkanals
ME00376B (me) * 2003-02-26 2011-10-10 Boehringer Ingelheim Pharma DIHIDROPTERIDINONI, POSTUPAK ZA NJlHOVO PRIPREMANJE I NJlHOVA PRIMJENA KAO LIJEK
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1784406A1 (de) * 2004-08-27 2007-05-16 Boehringer Ingelheim International GmbH Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2007014838A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Dihydropteridinones in the treatment of respiratory diseases
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
JP2009537500A (ja) * 2006-05-19 2009-10-29 アストラゼネカ アクチボラグ 増殖抑制剤としてのジヒドロプテリジン化合物
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008009909A1 (en) * 2006-07-17 2008-01-24 Astrazeneca Ab Pteridimones as modulators of polo-like kinase
WO2008040951A1 (en) * 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
EP1953163A1 (en) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinone derivatives as PI3-kinases inhibitors
AU2008228303B2 (en) 2007-03-22 2012-04-19 Takeda Pharmaceutical Company Limited Substituted pyrimidodiazepines useful as PLK1 inhibitors
WO2008157235A1 (en) * 2007-06-13 2008-12-24 University Of Virginia Patent Foundation Rsk inhibitors as anti-septicemia agents
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
MX2010001677A (es) * 2007-08-15 2010-03-11 Vertex Pharma Derivados de 4-(9-(3,3-difluorociclopentil)-5,7,7-trimetil-6-oxo-6 ,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-ilamino)-3-me toxibenzamida como inhibidores de las proteinas cinasas humanas plk1 a plk4 para el tratamiento de enfermedades proli
CN101917995A (zh) 2007-09-25 2010-12-15 武田药品工业株式会社 Polo样激酶抑制剂
WO2009071480A2 (en) * 2007-12-04 2009-06-11 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
US8765791B2 (en) 2008-03-11 2014-07-01 University Health Network Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
GB0807452D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd PLK inhibitors
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
WO2009153197A1 (en) 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Halo-substituted pyrimidodiazepines as plkl inhibitors
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
TWI557117B (zh) 2008-12-09 2016-11-11 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
MX2012003484A (es) * 2009-09-25 2012-04-20 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
CA2773827A1 (en) 2009-09-25 2011-03-31 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
KR101903925B1 (ko) 2009-10-26 2018-10-02 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
PH12012501122A1 (en) 2009-12-23 2012-10-29 Elan Pharm Inc Pteridinones as inhibitors of polo-like kinase
EP2536725B1 (en) * 2010-02-17 2015-10-28 Boehringer Ingelheim International GmbH Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EA034512B1 (ru) 2011-10-19 2020-02-14 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение злокачественной опухоли ингибиторами tor-киназы
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
US9006226B2 (en) 2012-02-23 2015-04-14 Boehringer Ingelheim International Gmbh Dihydropteridinones I
US8865716B2 (en) 2012-02-23 2014-10-21 Boehringer Ingelheim International Gmbh Dihydropteridinones II
AU2013202305B2 (en) 2012-02-24 2015-03-12 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP2016505041A (ja) 2013-01-16 2016-02-18 シグナル ファーマシューティカルズ，エルエルシー 置換型ピロロピリミジン化合物、その組成物、およびこれらを用いた治療方法
WO2014127816A1 (en) * 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones ii
JP6052527B2 (ja) * 2013-02-21 2016-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉ
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
UA115805C2 (uk) 2013-04-17 2017-12-26 Сігнал Фармасьютікалз, Елелсі Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
AU2014254057A1 (en) 2013-04-17 2015-11-05 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
EP2986609B1 (en) 2013-04-17 2019-06-19 Signal Pharmaceuticals, LLC Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
MX380689B (es) 2013-04-17 2025-03-12 Signal Pharm Llc Tratamiento de cancer con dihidropirazino-pirazinas.
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
ES2635003T3 (es) * 2013-07-09 2017-10-02 Bayer Pharma Aktiengesellschaft Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas inhibidoras de proteína BET
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CN103664845B (zh) * 2013-12-27 2016-02-10 湖南欧亚生物有限公司 一种Plk激酶抑制剂药物中间体7-氨基-2,3-二氢苯并呋喃-4-甲酸的制备方法
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
WO2015193229A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe
WO2015193228A1 (de) * 2014-06-19 2015-12-23 Bayer Pharma Aktiengesellschaft Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit para-substituierter aromatischer amino- oder ethergruppe
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
KR20170032473A (ko) 2014-08-08 2017-03-22 다나-파버 캔서 인스티튜트 인크. 디아제판 유도체 및 그의 용도
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
MX2017003288A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Metodos para preparar modulares de receptor tipo toll.
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN107257800B (zh) * 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
CR20180200A (es) 2015-09-11 2018-05-31 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas
HK1256419A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
DE102017005091A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one
DE102017005089A1 (de) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
AU2018289539B2 (en) 2017-06-22 2024-07-04 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection
CA3080941A1 (en) * 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Nek inhibitors and methods of use
AU2019257651B2 (en) 2018-04-24 2023-05-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
CN108610343A (zh) * 2018-06-12 2018-10-02 杨文思 一种用于治疗癌症的表皮生长因子受体抑制剂及其合成方法
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
CN113637017B (zh) * 2021-08-12 2024-03-26 中国药科大学 含二氢喋呤结构的化合物及其制备方法与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2645152B1 (fr) * 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
CA2029651C (en) * 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
YU18502A (sh) * 1999-09-15 2004-12-31 Warner-Lambert Company Pteridinoni kao inhibitori kinaza
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274340B2 (en) * 2004-08-14 2012-04-05 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl) benzamide, methods for the production thereof, and use thereof as medicaments

Also Published As

Publication number Publication date
HUP0401293A3 (en) 2008-03-28
BRPI0212137A2 (pt) 2016-06-28
PT1427730E (pt) 2006-11-30
EA200400368A1 (ru) 2004-12-30
YU27304A (sh) 2006-08-17
HUP0401293A2 (hu) 2004-10-28
IL160440A0 (en) 2004-07-25
KR100955589B1 (ko) 2010-04-30
ES2268093T3 (es) 2007-03-16
MXPA04002067A (es) 2004-06-07
JP3876254B2 (ja) 2007-01-31
NO328804B1 (no) 2010-05-18
CA2458699C (en) 2010-10-19
EA007062B1 (ru) 2006-06-30
AU2002337047B8 (en) 2003-03-18
CA2458699A1 (en) 2003-03-13
UY27427A1 (es) 2003-03-31
UA76512C2 (en) 2006-08-15
CY1105337T1 (el) 2010-03-03
DE50207522D1 (de) 2006-08-24
KR20040029465A (ko) 2004-04-06
EP1427730B1 (de) 2006-07-12
WO2003020722A1 (de) 2003-03-13
DK1427730T3 (da) 2006-11-06
ECSP045003A (es) 2004-04-28
IL160440A (en) 2009-09-01
NO20040680D0 (no) 2004-02-16
HRP20040213A2 (en) 2005-02-28
AR036586A1 (es) 2004-09-22
MY129751A (en) 2007-04-30
ATE332898T1 (de) 2006-08-15
NZ531928A (en) 2005-10-28
CO5560575A2 (es) 2005-09-30
CN1551881A (zh) 2004-12-01
PL369740A1 (en) 2005-05-02
RS51012B (sr) 2010-10-31
NO20040680L (no) 2004-02-16
EP1427730A1 (de) 2004-06-16
ZA200401365B (en) 2005-05-27
JP2005501904A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
AU2002337047B2 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
CA2517020C (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
US7759347B2 (en) 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
CA2700979C (en) Pyrimidine derivatives as protein kinase inhibitors
US8003786B2 (en) Dihydropteridinone compounds
JP5009155B2 (ja) 新規な６−ホルミル−テトラヒドロプテリジン、その製造方法および特に癌に対する医薬品としてのその使用
EP1786817A1 (de) Pteridinone als plk (polo like kinase) inhibitoren
CA2578838A1 (en) Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
KR20170131506A (ko) Ｍｅｋ 키나제 억제제에 대한 ｐ-톨루엔설포네이트 및 이의 결정형 및 이들의 제조 방법
US2807616A (en) Oxazolopyrimidines and method of preparing same
JP4484854B2 (ja) ジヒドロプテリジノン、その製造方法及び薬物形態での使用
HK1116195A (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
HK1089444B (en) Dihydropteridinones, method for the production and use thereof in the form of drugs

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 22, NO 2, PAGE(S) 235 UNDER THE HEADING APPLICATIONS ACCEPTED -NAME INDEX UNDER THE NAME BOEHRINGER INGELHEIM VETMEDICA GMBH, APPLICATION NUMBER 2002337047, UNDER INID (71), CORRECT THE APPLICANTS NAME TO READ BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired